News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pfizer Inc.'s Kidney Drug Also Slows Pancreatic Cancer
January 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Forbes -- Pfizer Inc., the world’s biggest drugmaker, said Friday a late-stage trial of Sutent reveals that the kidney cancer treatment also helps slow the growth of rare pancreatic neuroendocrine tumors.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Pfizer
MORE ON THIS TOPIC
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
·
2 min read
·
Heather McKenzie
IN PARTNERSHIP WITH API
Webinar: Lean Derisking: Taking Your Proof of Concept to the Clinic
February 24, 2026
·
1 min read
·
BioSpace Insights
Drug pricing
Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss
February 24, 2026
·
3 min read
·
Jef Akst
Cardiovascular disease
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
February 24, 2026
·
2 min read
·
Tristan Manalac
